A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias

PURPOSE: To determine the safety, target inhibition, and signals of clinical activity of tipifarnib in combination with bortezomib in patients with advanced acute leukemias. EXPERIMENTAL DESIGN: In a 3+3 design, patients received escalating doses of tipifarnib (days 1–14) and bortezomib (days 1, 4,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Lancet, Jeffrey E., Duong, Vu H., Winton, Elliott F., Stuart, Robert K., Burton, Michelle, Zhang, Shumin, Cubitt, Christopher, Blaskovich, Michelle A., Wright, John J., Sebti, Said, Sullivan, Daniel M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3049960/
https://ncbi.nlm.nih.gov/pubmed/21233404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1878
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi